Written by Mirjam Wuesthof and the CAM-Cancer Consortium.
Updated January 19, 2015

Mistletoe (Viscum album)

Evidence tables

Please view the PDFs listed below for details of the systematic reviews and/or controlled clinical trials included in this summary.

Table 1: systematic reviews of mistletoe for cancer

Table 2: controlled clinical trials of mistletoe for cancer

Citation Mirjam Wuesthof, CAM-Cancer Consortium. Mistletoe (Viscum album) [online document]. http://ws.cam-cancer.org/The-Summaries/Herbal-products/Mistletoe-Viscum-album. January 19, 2015.

References

  1. Mills S. The complete guide to modern Herbalism. Great Britain: Thorsons; 1994.
  2. Schulz V, Hänsel R, Tyler VE. Rational phytotherapy. A physician's guide to herbal medicine. 4th ed. Springer-Verlag; Berlin. 2001.
  3. Jung ML, Baudino S, Ribéreau-Gayon G et al. Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 1990; 51: 103-8.
  4. Kuttan G, Vasudevan DM, Kuttan R. Effect of a prepartion from Viscum album on tumour development in vitro and in mice. J Ethnopharmacol 1990; 29: 35-41.
  5. Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumour cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 1993; 43: 1221-7.
  6. Jurin M, Zarkovic N, Hrzenjak M, Hic Z. Antitumourous and immunomodulatory effects of the viscum album L. preparation Isorel. Oncology 1993; 50: 393-8.
  7. Mengs U, Göthel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 2002; 22: 1399-407.
  8. Kuttan G, Vasudevan DM, Kuttan R. Isolation and identification of a tumour reducing component from mistltoe extract (Iscador). Cancer Lett 1988; 41: 307-314.
  9. Hajto T. Immunomodulatory effects of Iscador: a Viscum album preparation. Oncology 1986; 43(Suppl): 51-65.
  10. Beuth J, Stoffel B, Ko HL et al. Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 1995; 45: 1240-2.
  11. Beuth J, Ko HL, Tunggal L, Steuer MK, Geisel J, Jeljaszewicz J. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo 1993; 7: 407-10.
  12. Stauder H, Kreuser ED. Mistletoe extracts standardised in terms of mistletoe lectins (ML 1) in oncology: current state of clinical research. Onkologie 2002; 25: 374-80.
  13. Lenartz D, Stoffel B, Menzel J et al. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumour destructive therapy in glioma patients. Anticancer Res 1996; 16 (6B): 3799-802.
  14. Heiny BM, Albrecht V, Beuth J. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 1998; 18 (1B): 583-6.
  15. Elluru SR, VAN Huyen JP, Delignat S et al. Antiangiogenic properties of Viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 2009; 29: 2945-50. 
  16. Kuttan G, Kuttan R. Reduction of leucopenia in mice by "Viscum album" administration during radiation and chemotherapy. Tumouri 1993; 79: 74-6.
  17. Beuth J, Ko HL, Tunggal L et al. Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice. In Vivo 1994; 8: 989-92.
  18. Gabius HJ, Gabius S, Joshi SS et al. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med 1994; 60: 2-7.
  19. Templeton A, Thürliman Beat, Baumann M et al. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer 2013, 13: 153.
  20. Micke O, Büntzel J, Kisters K et al. Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? Front Radiat Ther Oncol 2010; 42: 198-205.
  21. Buessing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis. Evid Based Complement Alternat Med 2012; 2012: 219402.
  22. Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9: 142-57.
  23. Kienle GS, Glockmann A, Schink M, et al. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009; 28: 79.
  24. Melzer J, Iten F, Hostanska K, Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed 2009; 16: 217-26.
  25. Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009; 9: 451.
  26. Horneber MA, Bueschel G, Huber R et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; 2: CD003297.
  27. Kleeberg UR, Suciu S, Bröcker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-a2b versus rIFN-g versus ISCADOR M1 versus observation after surgery in melanoma patients with either high risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
  28. Bar-Sela G, Wollner M, Hammer L et al. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 2013; 49: 1058-64.
  29. Kim KC, Yook JH, Eisenbraun J et al. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med 2012; 12: 172.
  30. Troeger W, Galun D, Reif M et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 2013; 49: 3788-97.
  31. Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised controlled trials. Int J Cancer 2003; 107: 262-7.
  32. Hutt N, Kopferschmitt-Kubler M, Cabalion J et al. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madr) 2001; 29: 201-3. 
  33. Helidxor. Helixor® manufacturer information “Fachinformation” 2014.   http://www.helixor.de/fileadmin/dateien/dokumente/Infomaterial_Anforderung/Fachinfo_2014-08-18_HELIXOR_AMP.pdf, accessed 13 January 2015.
  34. Weleda. Iscador® manufacturer information “Fachinformation” 2012. http://av.weleda.de/AVFachkreise/FI/Iscador M.pdf, accessed 13 January 2015.
  35. Rottapharm, Madaus. Lektinol® manufacturer information “Fachinformation” 2012. http://www.fachinfo.de/pdf/007642, accessed 13 January 2015.
  36. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17: 1-12.